Correlation between EPHX2 gene polymorphisms and coronary heart disease in Chinese population#br#
1.Department of Cardiology, Dingli Clinical Institute of Wenzhou Medical University, Wenzhou Central Hospital, Wenzhou, 325000; 2.Department of Cardiology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325015; 3.Department of Central Laboratory, Dingli Clinical Institute of Wenzhou Medical University, Wenzhou Central Hospital, Wenzhou,
325000
HUANG Yiwei1,ZHANG Huaiqin2,LIN Bin1, et al. Correlation between EPHX2 gene polymorphisms and coronary heart disease in Chinese population#br#[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2014, 44(8): 578-580.
Abstract： Objective: To study the correlation between EPHX2 gene polymorphisms and CHD in Chinese population. Methods: One hundred and seventy-six patients were underwent selected coronary angiography and patients having more than one major coronary vessel with at least 50% stenosis were defined as CHD. The control group consisted of 179 healthy subjects. rs2271001 polymorphisms were detected by polymerase chain reaction (PCR) and gene sequence. Results: Three kinds of genotypes at the rs2271001 were detected, and no deviation was observed from Hardy-Weinberg equilibrium. The frequency of allele G, A and genotype AG, GG and AA were increased in CHD group when compared with control group (P<0.05). Conclusion: These results suggest that rs2271001 A/G polymorphism be associated with CHD in Chinese population, the G allele may be a risk allele of CHD in Chinese Han nationality in Zhejiang province.
[1] Widlansky ME, Gokce N, Keaney JF, et al. The clinical im-
plications of endothelial dysfunction[J]. J Am Coll Cardiol,
2003, 42(7): 1149-1160.
[2] Abdu E, Bruun DA, Yang J, et al. Epoxyeicosatrienoic ac-
ids enhance axonal growth in primary sensory and cortical
neuronal cell cultures[J]. J Neurochem, 2011, 117(4): 632-
642.
[3] Sandberg M, Hassett C, Adman ET, et al. Identification and
functional characterization of human soluble epoxide hydrol-
ase genetic polymorphisms[J]. J Biol Chem, 2000, 275(37):
28873-28881.
[4] Lee CR, North KE, Bray MS, et al. Genetic variation in
soluble epoxide hydrolase (EPHX2) and risk of coronary
heart disease: The Atherosclerosis Risk in Communities
(ARIC) study[J]. Hum Mol Genet, 2006, 15(10): 1640-1649.
[5] Fornage M, Boerwinkle E, Doris PA, et al. Polymorphism
of the soluble epoxide hydrolase is associated with coronary
artery calcification in African-American subjects: The Cor-
onary Artery Risk Development in Young Adults (CARDIA)
study[J]. Circulation, 2004, 109(3): 335-339.
[6] Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J,
et al. Polymorphisms in human soluble epoxide hydrolase[J].
Mol Pharmacol, 2003, 64(2): 482-490.
[7] Ai D, Fu Y, Guo D, et al. Angiotensin II up-regulates soluble
epoxide hydrolase in vascular endothelium in vitro and in
vivo[J].Proc Natl Acad Sci USA, 2007, 104(21): 9018-9023.
[8] 蒋云, 许丹焰, 赵水平. 可溶性环氧化物水解酶抑制剂在
心血管领域中的研究进展[J]. 中国动脉硬化杂志, 2010,
18(2): 165-168.
[9] Nithipatikom K, Gross GJ. Review anticle: epoxyeicosa-
trienoic acids: novel mediators of cardioprotection[J]. Car-
diovasc Pharmacol Ther, 2010, 15(2): 112-119.
[10] Newman JW, Morisseau C, Hammock BD. Epoxide hydro-
lases: their roles and interactions with lipid metabolism[J].
Prog Lipid Res, 2005, 44(1): 1-51.
[11] Eldrup AB, Soleymanzadeh F, Farrown A, et al. Optimiza-
tion of piperidyl-ureas as inhibitors of soluble epoxide hy-
drolase[J]. Bioorg Med Chem Lett, 2010, 20(2): 571-575.
[12] Newman JW, Morisseau C, Harris TR, et al. The soluble ep-
oxide hydrolase encoded by EPXH2 is a bifunctional en-
zyme with novel lipid phosphate phosphatase activity[J].
Proc Natl Acad Sci USA, 2003, 100(4): 1558-1563.
[13] 许丹焰, 陈琛, 蒋云, 等. sEHi对冠心病患者内皮祖细胞功
能的影响[J]. 中南大学学报, 2010, 35(7): 685-692.
